Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553937 | 0.80 | EPHX1 (0.55) | EPHX1EPHX2LMNAALDH1A1KDM4E | |
| SCHEMBL14952209 | 0.78 | NPSR1 (0.41) | EPHX1EPHX2SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL3249206 | 0.76 | EPHX1 (0.60) | EPHX1EPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL3249205 | 0.76 | EPHX1 (0.60) | EPHX1EPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL18620682 | 0.76 | GLS (0.39) | SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL8164181 | 0.74 | ALDH1A1 (0.71) | EPHX1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL14424447 | 0.74 | EPHX1 (0.66) | EPHX1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8250809 | 0.74 | EPHX1 (0.70) | EPHX1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4136145 | 0.73 | EPHX1 (0.64) | EPHX1EPHX2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9112727 | 0.72 | LMNA (0.61) | EPHX1EPHX2SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030513-B2 | Rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100204376-A1 | Rheology Control Agents | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2010-08-12 | — | — | US | disclosed |
| US-7741510-B2 | Rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1838749-A1 | COATING COMPOSITIONS CONTAINING RHEOLOGY CONTROL AGENTS | E.I.Du pont de nemours and company (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006076715-A1 | COATING COMPOSITIONS CONTAINING RHEOLOGY CONTROL AGENTS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155021-A1 | Coating compositions containing rheology control agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20060155146-A1 | Rheology control agents | AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155146-A1 | Rheology control agents | HCRTR1, HCRTR2, REL | EPHX1 1092/4885EPHX2 608/4885SMN1; SMN2 3722/4885 |
| US-20100204376-A1 | Rheology Control Agents | HCRTR1, HCRTR2, REL | EPHX1 1092/4885EPHX2 608/4885SMN1; SMN2 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.